Brind.
  1. 10X Genomics underperformed the S&P 500 market so far this year.

10X Genomics stock fell short of S&P 500's gain on July 29, 2025.

1 report, 1 independent Updated Jul 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

10X Genomics stock fell short of S&P 500's gain on July 29, 2025.

Who's involved

What this event is mainly about
10X Genomics

Keep exploring

Part of

10X Genomics underperformed the S&P 500 market so far this year. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • StockStory10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings? 10x Genomics has been treading water for the past six months, holding steady at $14.80. The stock also fell short of the S&P 500’s 5.8% gain d